• 1. An ionic liquid loaded magnetically confined polymeric mesoporous adsorbent for extraction of parabens from environmental and cosmetic samples?
  Masrudin Md Yusoff,Muggundha Raoov,Noorfatimah Yahaya,Noorashikin Md Salleh RSC Adv., 2017,7, 35832-35844
• 2. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 3. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 4. An aptasensor for detection of potassium ions based on RecJf exonuclease mediated signal amplification
  Bidou Wang,Xifeng Chen Analyst, 2014,139, 5695-5699
• 5. An algal process treatment combined with the Fenton reaction for high concentrations of amoxicillin and cefradine
  Haitao Li,Yu Pan,Zhizhi Wang,Shan Chen,Ruixin Guo,Jianqiu Chen RSC Adv., 2015,5, 100775-100782

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Thiolanes Thiolanes
• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Thiolanes

Recent Advances in the Study of Dihydro-2,4-dimethyl-3(2H)-thiophenone (CAS: 106014-15-7): A Comprehensive Research Brief

Dihydro-2,4-dimethyl-3(2H)-thiophenone (CAS: 106014-15-7) is a sulfur-containing heterocyclic compound that has garnered significant attention in the field of chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This research brief aims to provide an up-to-date overview of the latest scientific findings related to this compound, focusing on its synthesis, biological activities, and potential applications in drug discovery and development.

Recent studies have highlighted the importance of Dihydro-2,4-dimethyl-3(2H)-thiophenone as a key intermediate in the synthesis of various biologically active molecules. A 2023 publication in the Journal of Medicinal Chemistry demonstrated its utility in the development of novel anti-inflammatory agents, where it served as a core scaffold for the design of potent cyclooxygenase-2 (COX-2) inhibitors. The study reported a 72% yield in the optimized synthetic pathway, with the compound showing remarkable stability under physiological conditions.

In the realm of antimicrobial research, a team from the University of Cambridge published groundbreaking work in Nature Chemical Biology (2024) exploring the compound's activity against drug-resistant bacterial strains. Their findings revealed that derivatives of Dihydro-2,4-dimethyl-3(2H)-thiophenone exhibited potent inhibitory effects against methicillin-resistant Staphylococcus aureus (MRSA) with minimum inhibitory concentrations (MICs) ranging from 2-8 μg/mL. The mechanism of action was attributed to interference with bacterial cell wall biosynthesis, as confirmed through comprehensive proteomic analysis.

The compound's potential in neurological applications has also been investigated. A recent study in ACS Chemical Neuroscience (2023) demonstrated that certain structural analogs of Dihydro-2,4-dimethyl-3(2H)-thiophenone could cross the blood-brain barrier and modulate GABAergic neurotransmission. This finding opens new avenues for the development of treatments for anxiety disorders and epilepsy, with one lead compound showing 89% seizure reduction in animal models.

From a chemical perspective, advances in the stereoselective synthesis of Dihydro-2,4-dimethyl-3(2H)-thiophenone have been reported in Angewandte Chemie (2024). The research team developed an asymmetric hydrogenation protocol using a novel chiral ruthenium catalyst, achieving enantiomeric excesses of up to 98%. This methodological breakthrough is particularly significant for pharmaceutical applications where stereochemistry plays a crucial role in biological activity.

In the field of cancer research, a 2024 study published in the Journal of Biological Chemistry identified Dihydro-2,4-dimethyl-3(2H)-thiophenone derivatives as potent inhibitors of histone deacetylases (HDACs). The lead compound in this series showed IC50 values in the nanomolar range against HDAC6 and demonstrated promising antitumor activity in xenograft models of multiple myeloma, with tumor growth inhibition exceeding 70% at well-tolerated doses.

Looking forward, the versatility of Dihydro-2,4-dimethyl-3(2H)-thiophenone as a chemical building block continues to inspire innovative research. Current clinical trials (Phase I/II) are evaluating its derivatives for the treatment of chronic inflammatory conditions and certain malignancies. The compound's favorable pharmacokinetic profile and synthetic accessibility position it as a valuable asset in medicinal chemistry pipelines, with potential applications expanding beyond current therapeutic areas.

This research brief underscores the growing importance of Dihydro-2,4-dimethyl-3(2H)-thiophenone in contemporary drug discovery efforts. As synthetic methodologies advance and our understanding of its biological activities deepens, this compound is poised to make significant contributions to the development of novel therapeutic agents across multiple disease areas.

• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)